Patent intelligence · US
US 11826322
Pre-filled syringe
Pre-filled syringe
Patent details — US 11826322
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 28, 2023
- Expiration
- Nov 23, 2043
- Applicant
- Teva Pharmaceuticals USA, Inc.
- Claims
- 27
- CPC classes
- A61K, A61K31/137, A61K47/02, A61K47/12
Quick answer
US 11826322 (Pre-filled syringe) is held by Teva Pharmaceuticals USA, Inc.. Status: granted. Granted Nov 28, 2023. Expires Nov 23, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Teva Pharmaceuticals USA, Inc.
- Grant date
- Expiration
- Claims
- 27
- CPC classes
- A61K, A61K31/137, A61K47/02, A61K47/12, A61K9/0019
More from Teva Pharmaceuticals USA, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12310929
Use of rasagiline for the treatment of restless legs syndrome
granted -
US 12258401
Anti-CD47 combination therapy
granted -
US 12157729
Solid state forms of Belumosudil and Belumosudil salts
granted -
US 12139528
Treating refractory migraine
granted -
US 12091388
Solid state forms of Reproxalap
granted -
US 11813359
Sustained release olanzapine formulations
granted -
US 11773083
Solid state forms of Belumosudil and Belumosudil salts
granted
Frequently asked questions
What is US patent 11826322?
US 11826322 (Pre-filled syringe) is held by Teva Pharmaceuticals USA, Inc.. Status: granted. Granted Nov 28, 2023. Expires Nov 23, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11826322?
Teva Pharmaceuticals USA, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 454 pharmaceutical patents for this assignee.
When does US 11826322 expire?
Our index shows an expiration date of Nov 23, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.